Canadian company to develop mock pandemic vaccine

Eggertson, Laura
March 2005
CMAJ: Canadian Medical Association Journal;3/1/2005, Vol. 172 Issue 5, p623
Academic Journal
Focuses on a mock pandemic vaccine being developed by Vancouver-based ID Biomedical Corp. to protect people against H5N1 influenza in British Columbia. Utilization of reverse genetics technology; Requirements for the phase II clinical trials; Comment from Michele Roy, spokesperson for ID Biomedical.


Related Articles

  • EXPANDED HUMAN TESTING OF NASAL FLU VACCINE BEGINS.  // Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p2 

    Announces the start of the expanded human safety and immunogenecity testing of the intranasal influenza vaccine from ID Biomedical Corporation.

  • Chiron's manufacturing misfortunes boost competitors. Sheridan, Cormac // Nature Biotechnology;Oct2005, Vol. 23 Issue 10, p1191 

    The article focuses on problems faced by Chiron Corp., the world's second largest flu vaccine supplier. Chiron's ongoing problems in influenza vaccine production have raised serious questions about the Emeryville, California company's future ability to compete in this particular segment of the...

  • Phase II data shows strong immunogenicity for ID Biomedical's FluINsure.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p7 

    Focuses on the clinical trials for FlulNsure, an intranasal, non-live, influenza vaccine developed by ID Biomedical Corp. Patients enrolled in the study; Presentation of the clinical study of FlulNsure; Evaluation on the efficacy of the influenza vaccine.

  • GSK catches flu shot.  // Chemical Market Reporter;9/12/2005, Vol. 268 Issue 8, p5 

    Reports that United States-based pharmaceutical firm Glaxosmithkline PLC continued its aggressive pursuit of a top slot in the flu vaccines arena with its bid for Vancouver, British Columbia-based ID Biomedical Corp. Worth of the bid; Benefit of the acquisition to Glaxosmithkline;...

  • Quadrivalent flu vaccine discussed. Blazek, Nicole // Infectious Diseases in Children;Mar2009, Vol. 22 Issue 3, p20 

    The article reports that U.S. health officials who attended the meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) have discussed the possibility of developing a quadrivalent influenza vaccine that would extend protection against the Victoria and Yamagata...

  • Universal flu vaccine? Kåhrström, Christina Tobin // Nature Reviews Microbiology;Nov2013, Vol. 11 Issue 11, p740 

    The article reports on a research finding which indicates that the use of virus-specific CD8+T cells in targeting conserved core proteins could be a blueprint for a universal flu vaccine.

  • Liposomal Influenza Vaccine. Holm, K.J.; Goa, K.L. // BioDrugs;1999, Vol. 11 Issue 2, p137 

    ▴ This trivalent liposomal influenza vaccine consists of purified influenza haemagglutinin inserted into a membrane of phosphatidylcholine and phosphatidylethanolamine. It contains 15µg of haemagglutinin per viral strain per dose. ▴ The vaccine is immunogenic in the elderly, in...

  • Industry News Headlines April 15, 2004 - May 14, 2004.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p20 

    Reports developments in the biotechnology industry as of April 2004. Acquisition of Shire Pharmaceuticals by ID Biomedical Corp.; Details on the lawsuit filed by Biota against GlaxoSmithKline PLC for failure to promote influenza drug; Sale of Zonegran, an ani-epiletic drug to Eisai Inc.

  • show case.  // Pharmacy Today;Feb2014, Vol. 20 Issue 2, p19 

    The article offers information on several drugs that were approved by the U.S. Food & Drug Administration including the H5N1 avian influenza vaccine from ID Biomedical Corp., the Raltegravir from Merck, and the Telmisartan immediate-release tablet angiotension II receptor blocker from Actavis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics